10-Q: BrightSpring Health Services Reports Strong Revenue and Adjusted EBITDA Growth, Strategic Divestiture Underway

BrightSpring Health Services, Inc. announced significant revenue and Adjusted EBITDA growth for Q2 and H1 2025, driven by its Pharmacy Solutions and Provider Services segments, alongside progress on its strategic divestiture of the Community Living business.

Summary

• Total revenues for the three months ended June 30, 2025, increased by $709.4 million, or 29.1%, to $3,147.7 million compared to the same period in 2024.
• Total revenues for the six months ended June 30, 2025, increased by $1,301.8 million, or 27.6%, to $6,025.8 million compared to the same period in 2024.
• Net income for the three months ended June 30, 2025, remained flat at $8.5 million, while for the six months, it improved significantly to $17.8 million from a net loss of $47.5 million in 2024.
• Adjusted EBITDA for the three months ended June 30, 2025, increased by $31.9 million, or 28.8%, to $142.5 million.
• Adjusted EBITDA for the six months ended June 30, 2025, increased by $60.7 million, or 28.5%, to $273.6 million.
• Adjusted EPS increased to $0.22 for Q2 2025 from $0.06 for Q2 2024, and to $0.42 for H1 2025 from $0.16 for H1 2024.
• The company entered into a definitive agreement on January 17, 2025, to sell its Community Living business for $835.0 million in cash, expected to close in late 2025.
• The company no longer qualifies as a controlled company under Nasdaq listing standards following a secondary public offering by KKR Stockholder and management in June 2025.
• Company leverage, as calculated under the First Lien Credit Agreement, improved to 3.64x at June 30, 2025, from 4.16x at December 31, 2024.
• Cash and cash equivalents increased to $70.070 million at June 30, 2025, from $60.954 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The company demonstrates strong financial performance with significant revenue and Adjusted EBITDA growth, improved leverage, and a positive shift in net income for the year-to-date. Strategic divestiture and focus on high-growth areas are positive. While gross margins slightly declined in Pharmacy Solutions and SG&A increased, the overall trajectory and strategic positioning are favorable.

Positives

• Strong revenue growth of 29.1% for Q2 2025 and 27.6% for H1 2025, indicating robust demand for services.
• Significant increase in Adjusted EBITDA by 28.8% for Q2 2025 and 28.5% for H1 2025, demonstrating improved operational profitability.
• Net income for the six-month period turned positive ($17.8 million) from a substantial loss ($47.5 million) in the prior year, reflecting overall financial improvement.
• Adjusted EPS saw a notable increase, rising from $0.06 to $0.22 for Q2 and from $0.16 to $0.42 for H1, indicating enhanced earnings power per share.
• Strategic divestiture of the Community Living business for $835.0 million is expected to streamline service offerings, increase strategic focus, and improve growth rates in target markets.
• Company leverage ratio improved to 3.64x from 4.16x, indicating a healthier debt profile.
• Successful management of interest expense, which decreased by 10.4% for Q2 and 17.6% for H1, due to lower variable rates and reduced outstanding debt.
• Continued expansion of pharmacy capabilities and growth in patient census and prescriptions (6% and 7% respectively in Q2 2025 for Pharmacy Solutions).
• Volume growth and rate increases in Provider Services, with Home Health Care revenue increasing by 17.1% in Q2 2025.
• Demonstrated ability to build de novo locations and facilitate integrated care, positioning for future organic growth.
• Transitioned from a controlled company to full compliance with Nasdaq corporate governance standards, potentially enhancing investor confidence.

Negatives

• Gross profit margin for Pharmacy Solutions decreased to 8.4% in Q2 2025 from 8.6% in Q2 2024, and to 8.2% in H1 2025 from 8.6% in H1 2024, due to mix shifts towards lower-margin specialty branded drugs and increased fulfillment costs.
• Net income for the three months ended June 30, 2025, remained flat at $8.5 million despite significant revenue growth, impacted by increased selling, general, and administrative expenses and income tax expense.
• Selling, general, and administrative expenses increased by 19.3% for Q2 2025 and 5.6% for H1 2025, partly due to acquisition, integration, and transaction-related expenses, as well as public company costs and IT investments.
• The company incurred a $12.7 million loss on extinguishment of debt in H1 2024 due to early repayment of the Second Lien Facility, which did not recur in H1 2025 but impacted prior period comparability.
• The company's effective tax rate for H1 2025 was 5.3%, significantly lower than 45.5% in H1 2024, but this was influenced by discrete tax benefits and limitations on executive compensation deductibility, indicating potential volatility in tax rates.

Risks

• Operating in a highly competitive industry.
• Inability to maintain relationships with existing patient referral sources or establish new ones.
• Changes to Medicare and Medicaid rates or methods governing payments for services.
• Cost containment initiatives of third-party payors, including post-payment audits.
• Implementation of alternative payment models and transition of Medicaid and Medicare beneficiaries to managed care organizations may limit market share and adversely affect revenues.
• Changes in the case mix of patients, as well as payor mix and payment methodologies.
• Reliance on federal and state spending, budget decisions, and continuous governmental operations, which may fluctuate under different political conditions.
• Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact profitability.
• Changes in relationships with pharmaceutical suppliers, including changes in drug availability or pricing.
• Reliance on the continual recruitment and retention of qualified personnel, including nurses, pharmacists, therapists, caregivers, direct support professionals, and senior management.
• Compliance with or changes to federal, state, and local laws and regulations that govern employment practices, including minimum wage, living wage, and paid time-off requirements.
• Fluctuation of results of operations on a quarterly basis.
• Harm caused by labor relation matters.
• Limitations in ability to control reimbursement rates received for services if costs cannot be maintained or reduced.
• Delays in collection or non-collection of accounts receivable, particularly during the business integration process.
• Failure to manage growth effectively, which may inhibit the ability to execute the business plan, maintain high levels of service and satisfaction, or adequately address competitive challenges.
• Ability to identify, successfully complete, and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of the Community Living business.
• Ability to continue to provide consistently high quality of care.
• Maintenance of corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of services.
• Contract continuance, expansion, and renewal with existing customers, including renewals at lower fee levels, customers declining to purchase additional services, or reduction in services received.
• Effective investment in, implementation of improvements to, and proper maintenance of the uninterrupted operation and data integrity of information technology and other business systems.
• Security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information, cause a loss of confidential data, or prevent access to critical information, exposing the company to liability, litigation, and governmental inquiries.
• Risks related to credit card payments and other payment methods.
• Potential substantial malpractice or other similar claims.
• Various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance.
• Current insurance program may expose the company to unexpected costs, particularly if losses are not covered or claims differ from estimates.
• Factors outside of control, including those listed, which could require recording an asset impairment of goodwill.
• A pandemic, epidemic, or outbreak of an infectious disease.
• Inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, or strikes.
• Inability to adequately protect intellectual property rights.
• Risks related to compliance with the regulatory framework.
• Interests of KKR Stockholder may conflict with stockholders' interests in the future.
• Substantial indebtedness.
• Significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, which could result in supply chain disruptions and significant increases in costs.
• Interest rate risk: A hypothetical 1% increase in interest rates would decrease net income and cash flows by $5.3 million on an annual basis based upon borrowing levels at June 30, 2025.
• Inflation: Wages and other expenses increase during periods of inflation and labor shortages, particularly for qualified caregivers, with limited ability to pass on increased costs for Medicare and Medicaid patients.

Future Outlook

The company expects the divestiture of its Community Living business to streamline service offerings, increase strategic focus, enhance operational efficiencies, refine its payer mix, and improve clinical integration and business synergy across the Provider Services segment. This divestiture is also anticipated to augment revenue and Adjusted EBITDA growth rates and maximize exposure to target growth markets such as home health, rehab, primary care, and hospice. The company plans to continue selectively and strategically expanding its footprint within the United States through de novo locations and extending service offerings, believing there are substantial opportunities to deliver more integrated care to its patient populations.

Management Comments

• The divestiture of the Community Living business provides for continuity of important intellectual and developmental disability services while BrightSpring focuses on a concentrated group of customers, patients and stakeholders in the future.
• The company's streamlined service offerings will result in increased strategic focus, operational efficiencies, a refined payer mix, and greater clinical integration and business synergy across the Provider Services segment.
• The divestiture will also augment expected Revenue and Adjusted EBITDA growth rates and maximize exposure to target growth markets that require BrightSprings needed and valuable solutions, such as home health, rehab, primary care, and hospice.
• Our pharmacy has grown patient census and prescriptions by approximately 6% and 7%, respectively, in the second fiscal quarter of 2025 compared to the second fiscal quarter of 2024.
• We are a leading independent pharmacy provider in our respective pharmacy patient markets, and we expect to continue to increase our share, including home infusion patients, specialty oncology patients, behavioral patients, in-home Seniors, and hospice patients.
• Given the proven value proposition of home-based health services, we believe patients will increasingly seek treatment and referral sources and payors will increasingly support treatment in homes more often than in higher cost, less convenient, higher acuity institutional settings.
• We have observed relatively stable reimbursement rates from government and commercial payors in our pharmacy and provider services over a number of years, particularly for services provided to high-need, medically complex populations.
• Quality and compliance are central to our strategies and mission. We have demonstrated leading and excellent service and customer/patient/family satisfaction scores across the organization.
• We have continued to make investments in automation, data, and technology systems to support enhanced workflows, further scale, and future growth across service lines.
• We believe our platform can continue to build further scale nationally, adding density to additional and targeted key markets as a lever to facilitate maximum pharmacy and provider services overlap, integrated and value-based care, and growth.
• Our operating model consists of complementary pharmacy and provider services that high-need Senior and Specialty populations require, and it is designed to increasingly coordinate, manage, and serve patients across our various needs and settings over time, leading to improved patient, family, physician, and referral source satisfaction, improved payor experiences, and better outcomes.
• The company's focused build out of its Home-Based Primary Care, transitional care programs, and in-home medication therapy management, and Clinical (Nursing) Hub, are key enablers to coordinate base pharmacy and provider services and drive improved quality and lower costs for value-based care constructs.

Industry Context

BrightSpring Health Services operates within the growing home and community-based healthcare services sector, which is benefiting from an aging population and a shift towards lower-cost, patient-preferred care settings. The company's integrated model, combining pharmacy solutions and provider services, positions it to address the complex needs of senior and specialty patient populations. Its strategic divestiture of the Community Living business aligns with a broader industry trend of companies streamlining portfolios to focus on core, high-growth segments. The emphasis on value-based care models and expansion into home health, rehab, primary care, and hospice reflects the evolving reimbursement landscape and demand for coordinated, cost-effective care.

Comparison to Industry Standards

• The company states it has 'demonstrated consistently high and often leading marks for service levels, satisfaction scores, and quality metrics in our industries,' but does not provide specific comparable companies, projects, or results to benchmark against.
• The filing notes that 'pharmacy solutions delivered to and tailored for the home environment, such as home infusion services, oncology services, and daily medication management services in the home, will continue to grow faster than the overall and general pharmacy market,' indicating alignment with high-growth segments.

Management Changes

Corporate Governance

Legal Proceedings

• The 'Silver matter' litigation, filed on March 4, 2011, against PharMerica for alleged False Claims Act violations, was settled. The total financial impact of the settlement was $120.0 million, with payments of $90.0 million in June 2024, $20.0 million in July 2024, and the remaining $10.0 million in April 2025. The case was dismissed with prejudice on July 3, 2024.
• The company is party to various other legal and/or administrative proceedings arising out of the operation of its programs and in the ordinary course of business. Management does not believe the ultimate liability for these, in excess of amounts already provided, will have a material adverse effect on consolidated financial condition, results of operations, or cash flows.

Related Party Transactions

• The Monitoring Agreement with KKR and WBA, which required payment of an aggregate advisory fee equivalent to 1% of consolidated EBITDA, terminated upon the completion of the IPO Offerings in January 2024. The company recognized $0.7 million in monitoring and advisory fees during Q1 2024 and paid $22.7 million in termination fees to KKR and WBA in Q4 2024 (recognized in Q1 2024).
• KKR Capital Markets LLC (KCM), a wholly owned subsidiary of KKR, acted as an underwriter in the IPO Offerings during Q1 2024, receiving $7.4 million in underwriting discounts and commission. The company also paid KCM $1.9 million in underwriter, arranger, and transaction fees in Q1 2024 related to debt refinancing. No similar fees were paid to KCM during Q2 2024 or Q1/Q2 2025.
• Walgreens Boots Alliance, Inc. (WBA) sold its remaining ownership interests in the company through open market transactions during Q2 2025 and is no longer considered a related party. The WBAD Membership Agreement with WBA was terminated in Q1 2025, and the company entered into a separate agreement with AmerisourceBergen Drug Corporation (ABDC) on February 1, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and Adjusted EBITDA growth, improved leverage, and strategic focus. The secondary offering by KKR and management could increase liquidity but did not directly benefit the company financially (except for stock option exercises). The change in controlled company status may enhance governance.
• Employees: Potential impact from the divestiture of the Community Living business, as those employees will transition to National Mentor Holdings, Inc. The company's focus on recruitment and retention of qualified personnel is critical given labor shortages in the healthcare industry.
• Customers/Patients: The strategic divestiture aims to streamline service offerings and enhance clinical integration, potentially leading to more focused and higher-quality care for senior and specialty populations. Continued investment in technology and integrated care models should improve patient outcomes and satisfaction.
• Suppliers: Changes in relationships with pharmaceutical suppliers (e.g., new agreement with ABDC after WBAD termination) could impact supply chain dynamics and costs.
• Creditors: Improved company leverage and reduced interest expense are positive for creditors, indicating better debt servicing capacity. Compliance with debt covenants provides stability.

Next Steps

• Close the divestiture of the Community Living business to National Mentor Holdings, Inc., expected in late 2025.
• Continue to comply with all applicable corporate governance requirements of Nasdaq, subject to phase-in rules, now that the company is no longer a controlled company.
• Selectively and strategically expand the company's footprint within the United States and extend service offerings to patients and customers through de novo locations.
• Further develop and implement integrated care opportunities across pharmacy and provider services.
• Continue aligning with value-based care reimbursement models and building out Home-Based Primary Care, transitional care programs, in-home medication therapy management, and Clinical (Nursing) Hubs.

Key Dates

Recommendation

The filing indicates strong operational performance with significant revenue and Adjusted EBITDA growth across core segments. The strategic divestiture of the Community Living business, while substantial, is aimed at streamlining operations and focusing on higher-growth, higher-margin areas, which is a positive long-term strategic move. The improvement in the company's leverage ratio and the positive shift in net income for the year-to-date period are encouraging. While there are inherent risks in the healthcare sector and some margin compression in Pharmacy Solutions, the overall financial trajectory and strategic clarity suggest a favorable outlook for investors seeking exposure to the home and community-based healthcare market.

Keywords

Healthcare Services, Pharmacy Solutions, Provider Services, Home Health, Hospice, Rehabilitation, Personal Care, SEC Filing, 10-Q, Financial Results, EBITDA, Revenue Growth, Divestiture, Acquisitions, Corporate Governance, Medicare, Medicaid, Specialty Pharmacy, Infusion Pharmacy, Managed Care, Value-Based Care, Debt Management, Risk Factors